JP2011525523A5 - - Google Patents

Download PDF

Info

Publication number
JP2011525523A5
JP2011525523A5 JP2011515372A JP2011515372A JP2011525523A5 JP 2011525523 A5 JP2011525523 A5 JP 2011525523A5 JP 2011515372 A JP2011515372 A JP 2011515372A JP 2011515372 A JP2011515372 A JP 2011515372A JP 2011525523 A5 JP2011525523 A5 JP 2011525523A5
Authority
JP
Japan
Prior art keywords
fviii
buffer
ligand
resin
multimodal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011515372A
Other languages
English (en)
Japanese (ja)
Other versions
JP5619738B2 (ja
JP2011525523A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/057883 external-priority patent/WO2009156430A1/en
Publication of JP2011525523A publication Critical patent/JP2011525523A/ja
Publication of JP2011525523A5 publication Critical patent/JP2011525523A5/ja
Application granted granted Critical
Publication of JP5619738B2 publication Critical patent/JP5619738B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011515372A 2008-06-24 2009-06-24 凝固第viii因子の精製方法 Active JP5619738B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12940208P 2008-06-24 2008-06-24
EP08158893 2008-06-24
US61/129,402 2008-06-24
EP08158893.1 2008-06-24
PCT/EP2009/057883 WO2009156430A1 (en) 2008-06-24 2009-06-24 A process of purifying coagulation factor viii

Publications (3)

Publication Number Publication Date
JP2011525523A JP2011525523A (ja) 2011-09-22
JP2011525523A5 true JP2011525523A5 (https=) 2012-08-09
JP5619738B2 JP5619738B2 (ja) 2014-11-05

Family

ID=40076764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011515372A Active JP5619738B2 (ja) 2008-06-24 2009-06-24 凝固第viii因子の精製方法

Country Status (19)

Country Link
US (1) US8329871B2 (https=)
EP (2) EP2300497B1 (https=)
JP (1) JP5619738B2 (https=)
KR (3) KR101804136B1 (https=)
CN (1) CN102066417B (https=)
AU (1) AU2009264282B2 (https=)
BR (1) BRPI0914695B1 (https=)
CA (1) CA2728047C (https=)
DK (2) DK2537862T3 (https=)
ES (2) ES2538706T3 (https=)
IL (3) IL209758A (https=)
MX (1) MX2010013908A (https=)
PL (1) PL2300497T3 (https=)
PT (1) PT2300497E (https=)
RU (2) RU2698392C2 (https=)
SI (1) SI2300497T1 (https=)
UA (1) UA100901C2 (https=)
WO (1) WO2009156430A1 (https=)
ZA (1) ZA201009162B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730707B (zh) 2007-07-11 2014-12-17 诺沃-诺迪斯克有限公司 使用混合式或多模式树脂来纯化因子ⅷ
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
WO2010026186A1 (en) * 2008-09-03 2010-03-11 Octapharma Ag New protecting compositions for recombinantly produced factor viii
US20110166332A1 (en) * 2008-09-12 2011-07-07 Ge Healthcare Bio-Sciences Ab Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
KR101951446B1 (ko) * 2010-03-30 2019-02-22 옥타파마 아게 성장 인자 단백질을 정제하는 방법
WO2011121020A1 (en) * 2010-03-30 2011-10-06 Octapharma Ag A process for purifying vitamin k dependent proteins such as coagulation factor ix
CA2796729C (en) 2010-04-20 2020-06-23 Octapharma Ag Melezitose for stabilizing human blood plasma proteins
WO2012049285A1 (en) 2010-10-14 2012-04-19 Octapharma Ag A method for the quantitative glycosylation analysis of proteins
BR112013007237A2 (pt) 2010-11-05 2016-06-14 Hoffmann La Roche ''método para produzir um anticorpo anti-ig-1r''
ES2970057T3 (es) * 2011-05-13 2024-05-24 Octapharma Ag Un procedimiento para aumentar la productividad de células eucarióticas en la producción de FVIII recombinante
KR102001662B1 (ko) 2011-06-17 2019-10-01 학교법인 히가시-니뽄-가쿠엔 루프스 안티코아귤란트 검출용 혈액 응고시간의 측정방법
US20130109807A1 (en) * 2011-10-26 2013-05-02 Bio-Rad Laboratories, Inc. Removal of virucidal agents in mixed mode chromatography
WO2014066471A1 (en) * 2012-10-24 2014-05-01 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
US20140154233A1 (en) * 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
CN103880947B (zh) * 2012-12-21 2016-01-13 武汉禾元生物科技股份有限公司 一种分离纯化高纯度重组人血清白蛋白的层析方法
AU2014226126B2 (en) * 2013-03-08 2019-02-14 Genzyme Corporation Continuous purification of therapeutic proteins
WO2014201400A2 (en) * 2013-06-13 2014-12-18 Biogen Idec Ma Inc. Anti-factor viii antibodies or uses thereof
WO2015005960A1 (en) 2013-07-12 2015-01-15 Emd Millipore Corporation Removal of fragments from a sample containing a target protein using activated carbon
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
TWI709570B (zh) * 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
RU2695428C2 (ru) * 2014-01-20 2019-07-23 Октафарма Аг СПОСОБ ПРОИЗВОДСТВА ФАКТОРА VIII, ИМЕЮЩЕГО УЛУЧШЕННОЕ СООТНОШЕНИЕ FVIII:C/FVIII:Ag
ES2810813T3 (es) * 2014-01-24 2021-03-09 Am Pharma Bv Procesamiento para recuperación y purificación de una fosfatasa alcalina
WO2015120056A1 (en) 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CN104861060A (zh) * 2014-02-21 2015-08-26 神州细胞工程有限公司 一种纯化凝血因子viii的方法
US10259851B2 (en) 2014-05-29 2019-04-16 Agency For Science, Technology And Research Protein extraction methods
US10626164B2 (en) * 2014-07-25 2020-04-21 Csl Limited Purification of VWF
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
WO2016207328A1 (en) * 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
EP3205665A1 (en) 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
GB201617240D0 (en) * 2016-10-11 2016-11-23 Profactor Pharma Ltd Purification process
US11299533B2 (en) 2017-06-23 2022-04-12 Takeda Pharmaceutical Company Limited Purification of factor VIII subspecies
CN107226859B (zh) * 2017-08-10 2020-11-24 博雅生物制药集团股份有限公司 一种人凝血因子ⅷ的制备方法
EP3676375A4 (en) * 2017-08-31 2021-04-07 Green Cross Corporation PROCESS FOR PURIFYING A SULFATASE PROTEIN
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
AU2019332764B2 (en) 2018-08-31 2025-05-29 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
EP4093745A4 (en) * 2020-01-20 2024-03-06 Wuxi Biologics Ireland Limited NEW WASH BUFFER SOLUTION FOR AFFINITY CHROMATOGRAPHY
CN118217951B (zh) * 2024-04-01 2025-05-23 山东建筑大学 一种水中的高纯度磷回收装置和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US5316680A (en) * 1992-10-21 1994-05-31 Cornell Research Foundation, Inc. Multimodal chromatographic separation media and process for using same
WO1994029992A1 (en) 1993-06-11 1994-12-22 Northern Telecom Limited Method and apparatus for providing user controlled call management services
DE4337573C1 (de) * 1993-11-04 1995-05-18 Octapharma Ag Verfahren zur Herstellung einer virusinaktivierten Faktor VIII enthaltenden Fraktion mittels chromatographischer Methoden
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
AUPR638801A0 (en) * 2001-07-13 2001-08-09 Life Therapeutics Limited Factor viii separation
KR101150050B1 (ko) * 2004-02-27 2012-07-05 지이 헬스케어 바이오-사이언시스 에이비 항체 정제 방법
WO2005121163A2 (en) * 2004-06-07 2005-12-22 Upfront Chromatography A/S Isolation of plasma or serum proteins
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
FR2887883B1 (fr) * 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
AR062069A1 (es) * 2006-07-14 2008-10-15 Genentech Inc Replegado de proteinas recombinantes
RU2324495C1 (ru) * 2006-08-31 2008-05-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения препарата фактора свертывания viii крови человека
US8022187B2 (en) * 2007-02-01 2011-09-20 Baxter International Inc. FVIII-independent FIX-mutant proteins for hemophilia A treatment
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのvwf安定化fviii製剤及びfviiiなしのvwf製剤の使用
CN101730707B (zh) * 2007-07-11 2014-12-17 诺沃-诺迪斯克有限公司 使用混合式或多模式树脂来纯化因子ⅷ
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie

Similar Documents

Publication Publication Date Title
JP2011525523A5 (https=)
RU2011102437A (ru) Способ очистки фактора свертывания крови viii
CA2784278C (en) Wash solution and method for affinity chromatography
CN101730707B (zh) 使用混合式或多模式树脂来纯化因子ⅷ
CN102858971B (zh) 纯化维生素k依赖性蛋白如凝血因子ix的方法
RU2015149979A (ru) Способ очистки белка фактора роста
JPWO2015041218A1 (ja) 新規抗体精製方法及びそれから得られる抗体(NovelAntibodyPurificationMethodandAntibodyobtainedtherefrom)、並びに陽イオン交換基を用いた新規抗体精製法及びそれから得られる抗体(NovelAntibodyPurificationmethodusingCationExchangerandAntibodyobtainedtherefrom)
ES2552337T3 (es) Procedimientos para la preparación de plasminógeno
JP2019528255A5 (https=)
JP2022023814A (ja) 組換え生産された三量体型のrsvタンパク質の精製方法
WO1995004077A1 (en) Method of purifying plasminogen
CN103282045A (zh) 因子viii水溶液
CN109803982A (zh) Fviii的纯化过程
JP2017517514A (ja) Hmg−up(超高純度グレードのヒト閉経期ゴナドトロピン)を得るための方法及び夾雑物を含まない組成物
EA040179B1 (ru) Способ очистки fviii или его варианта с удаленным доменом b от клеточной культуры in vitro